| Summary: | 碩士 === 國立中山大學 === 生物醫學研究所 === 106 === Cisplatin is one of the most effective anticancer drugs used for treatment of tumors, including bladder, small cell lung and ovarian cancers. During the cisplatin treatment of urothelial cancer, some patients will become to be cisplatin resistance, and then it will influence the outcome of treatment. Therefore, it is an important topic how to characterize the cisplatin-resistant mechanism in human urinary bladder urothelial carcinoma (UBUC) cells. B-cell lymphoma 6 protein is transcription repressor and interaction with transcription factor, regulates gene expression. BCL6 is proto-oncogene and it inhibit DNA repair pathways and TP53 protein. According to the report, we find that the BCL6 overexpression in many cancer cell. Our use the array comparative genomic hybridization, explore the BCL6 overexpression in bladder cancer cell. Thus, we suspect that BCL6 have the important role in bladder cancer. To evaluate the BCL6 gene in urinary bladder urothelial carcinoma-derived cell lines would sensitize their responses to cisplatin and study the underlying molecular mechanisms.
|
|---|
